Due to unforeseen circumstances, the JPM webinar has been cancelled. We thank you for your understanding and apologize for any inconvenience caused. Please be sure to subscribe to the Event Series to receive updates of upcoming webinars.
Welcome from the Chair
3rd Webinar on Personalized Medicine
Radiation Response Biomarkers for Individualised Cancer Treatments
I am pleased to welcome you to this 2nd Webinar on Radiation responses biomarkers for individualised cancer treatments.
This webinar follows the Journal of Personalised Medicine special issue on Radiation Response Biomarkers for Individualised Cancer Treatments for which I was Guest Editor.
Biomarkers are essential for predicting and/or monitoring radiation exposure-associated effects. The aim of this Special Issue was to present an insight into the ongoing state-of-the-art research in the field of improvements in the precision of dose delivery during radiotherapy treatment and in the field of radiation response biomarker for applications in personalised medicine. The main goals being to allow individual specificities and differences in sensitivity to be considered to offer tailored treatments and/or better protect those at higher risk.
Date: 12 December 2022
Time: 2:30 pm CET | 8:30 am EST | 9:30 pm CST Asia
Webinar ID: 853 0888 6542
Webinar Secretariat: email@example.com
Cancer Mechanisms and Biomarkers Group, Radiation Effects Department, Harwell Campus, Chilton, Didcot, United Kingdom, UK Health Security Agency
I am biologist who carried out a PhD in Radiobiology-Radiopathology I worked on inter-individual radiation sensitivity and DSB repair. I identified the first radiotherapy patient whose radiation toxicity was due to a defect in DNA DSB repair which was thought to be almost incompatible with survival at the time; it was found later that the patient had a mutation in ligase IV. we are trying to better understand the mechanisms by which acute or protracted ionising radiation exposure either of natural or medical origin interacts and affects cells and individuals. I also work on identifying and validating new biomarkers of radiation exposure, susceptibility and toxicity and in cancer genomics to identify mutational signatures of ionizing radiation in second malignancies. Since 2005, I am leading the Cancer Mechanisms and Biomarkers group at UKHSA.
Dana-Farber/Harvard Cancer Center, Boston, USA
Dr. Sayeda Yasmin-Karim is an instructor in the Division of Medical Physics and Biophysics. Her research interests include the enhancement of anti-tumor activity using different nanomaterials, phytomedicine, immunotherapy and radiation in animal models.
Department of Neurology, Stony Brook University Hospital, Stony Brook, NY, USA
Dr. Anat Biegon is Professor of Radiology (primary) and Neurology at Stony Brook University Renaissance School of Medicine. Professor Anat Biegon research interests include: Brain response to traumatic, ischemic or inflammatory insults; Sex differences and gonadal hormone modulation of brain function in health and disease; Development and validation of radiopharmaceuticals for non-invasive imaging of neurotransmitter and hormone markers in brain disorders and cancer.
This is a FREE webinar. The number of participants to the live session is limited but the recording will be made available on Sciforum shortly afterwards. Registrations with academic institutional email addresses will be prioritized.
Certificates of attendance will be delivered to those who attend the live webinar.
Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.
Time in CET
Chair Dr. Christophe Badie
2:30 - 2:40 pm
Dr. Sayeda Yasmin-Karim
Role of Immune-Adjustments for Personalized Radiotherapy
2:40 - 3:00 pm
Prof. Dr. Anat Biegon
Diagnostic Accuracy and Secondary Cancer Risk of Radiation Are Modulated by Biological Sex and Gonadal Hormones
3:00 - 3:20 pm
3:20 - 3:40 pm
Closing of Webinar
Chair Dr. Christophe Badie
3:40 - 3:45 pm
Guest Editors: Dr. Christophe Badie and Dr. Eric Andreas Rutten
Deadline for manuscript submissions: closed (10 December 2020)